2023 Special Meeting Materials

Special Meeting Proxy Statement

Special Meeting Proxy Statement

View an enhanced version of the Special Meeting Proxy Statement.

Proxy Supplement

Proxy Supplement

View an enhanced version of the Proxy Supplement.

You may request paper copies of the proxy materials by phone, email or online. 

To request by phone dial 866-648-8133.

Vote Now

Vote your proxy online now or by phone at 866-230-6355.

Meeting Details

Date:

Thursday, January 5, 2023

Time:

10:00 a.m. Eastern Time

Location:

Wilmer Cutler Pickering Hale and Dorr LLP
60 State Street, 26th Floor
Boston, MA 02109

2022 Investor Materials

Annual Report

Annual Report

View an enhanced version of the Annual Report.

Proxy Statement

Proxy Statement

View an enhanced version of the Proxy Statement.

About Us

AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology and other novel targeted combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the company.

To learn more visit us at www.aveooncology.com.